As a glucagon-like peptide-1 (GLP-1) receptor agonist, Semaglutide mimics the action of endogenous GLP-1, a hormone integral to glucose metabolism and appetite regulation
This can be particularly valuable for individuals dealing with chronic health conditions, autoimmune disorders, or exposure to environmental toxins, as the therapy helps optimize the bodys natural defense mechanisms
First, this was an open-label, Phase II trial (lacks blinding), the duration of the study and follow-up were short, and thus, no data on hard outcomes, such as CV disease risk reduction and mortality, were analyzed
it translates into measurable, clinical improvements for patients battling the complex sequelae of post-viral syndromes
Lee SG, Chae J, Woo SM, Seo SU, Kim HJ, Kim SY, Schlaepfer DD, Kim IS, Park HS, Kwon TK, Nam JO
Inhibition of NNMT has been shown to reduce fat accumulation and increase energy expenditure in preclinical models